|U.S. Biopharmaceutical Market|
|Business Reports - Market Report|
U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016)
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.
This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. While it looks at the overall market size and presents forecast till 2016, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has led to the metamorphosis of the pharmaceutical industry, resulting in the subset industry of biopharmaceuticals. The big players in the pharma industry, including Pfizer, Merck, and Novartis, have been the first few to reap the benefits of investing in biotechnology through both organic as well as inorganic growth mechanisms.
Market forecasts include the biopharmaceuticals currently in the market as well as those projected to enter the market by the end of the forecast period in 2016. Market challenges, drivers, and restraints have also been identified and assessed. Selected late stage pipeline analysis is also included.
This report analyzes the biopharmaceutical industry's products, features, companies, market size and potential, and patent portfolios. The impact of the Medicare and Medicaid policies and individual plan behaviors on the biopharmaceutical industry is also discussed.
Newer news items
|< Prev||Next >|
Regulatory Affairs for EU & USA